Lexeo Therapeutics (LXEO) said Wednesday it has seen "positive" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.
Treatment with the gene therapy candidate resulted in "dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes," the company said.
The candidate drug also showed a "favorable safety profile," the company said.
Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.
The company's shares fell nearly 10% in recent trading.
Price: 8.98, Change: -0.99, Percent Change: -9.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.